90731-96-7

Basic information

• Product Name: PYRIDINE, 3-BROMO-4-(1-METHYLETHYL)-
• Synonyms: PYRIDINE, 3-BROMO-4-(1-METHYLETHYL)-;3-Bromo-4-isopropylpyridine
• CAS NO: 90731-96-7
• Molecular Formula: C8H10BrN
• Molecular Weight: 200.078
• Mol File: 90731-96-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 229.4±20.0 °C(Predicted)
• Appearance: /
• Density: 1.343±0.06 g/cm3(Predicted)
• PKA: 3.58±0.18(Predicted)
• CAS DataBase Reference: PYRIDINE, 3-BROMO-4-(1-METHYLETHYL)-(CAS DataBase Reference)
• NIST Chemistry Reference: PYRIDINE, 3-BROMO-4-(1-METHYLETHYL)-(90731-96-7)
• EPA Substance Registry System: PYRIDINE, 3-BROMO-4-(1-METHYLETHYL)-(90731-96-7)

Safety Data

• Hazardous Substances Data: 90731-96-7(Hazardous Substances Data)

Usage

General Description

3-Bromo-4-(1-methylethyl)pyridine is an organic compound with a molecular formula C8H10BrN. It is a derivative of pyridine, with a bromine atom at the 3-position and an isopropyl group at the 4-position. This chemical is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is also used as a building block in the production of various fine chemicals. 3-Bromo-4-(1-methylethyl)pyridine has potential applications in the field of medicinal chemistry and drug discovery, making it an important compound for research and development in the pharmaceutical industry.

Upstream product

• 626-55-1 3-Bromopyridine 
• 807329-97-1 TurboGrignard 

Relevant articles and documents

KRAS G12D INHIBITORS

The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

PYRIDINYL PYRAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Transition-metal-free BF3-mediated regioselective direct alkylation and arylation of functionalized pyridines using grignard or organozinc reagents

A formal regioselective cross-coupling of various pyridines with alkyl and aryl groups can be achieved by a BF3·OEt2-mediated addition of Grignard or organozinc reagents to pyridines bearing various substituents (chloro, bromo, cyano, vinyl, phenyl, carbethoxy, nitro, etc.) followed by an oxidative aromatization mediated by chloranil. Good regioselectivity and wide functional group tolerance make this method very versatile for the preparation of polyfunctional pyridines. No transition-metal catalyst is required in these coupling reactions.